Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7
Oppenheimer Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $12
MannKind's Growth Momentum and Increased Confidence in Pipeline Elevate Buy Rating
RBC Capital Sticks to Its Hold Rating for MannKind (MNKD)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Hims & Hers Health (HIMS) and MannKind (MNKD)
Leerink Partners Initiates MannKind(MNKD.US) With Buy Rating, Announces Target Price $8
MannKind Price Target Announced at $8.00/Share by Leerink Partners
MannKind Analyst Ratings
Oppenheimer Maintains MannKind(MNKD.US) With Buy Rating, Raises Target Price to $12
Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)
MannKind's Strong Q2 Performance and Promising Pipeline Merit a Buy Rating
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Envista Holdings (NVST) and Soleno Therapeutics (SLNO)
MannKind (MNKD) Gets a Hold From RBC Capital
MannKind Analyst Ratings
Rodman & Renshaw Initiates Coverage On MannKind With Buy Rating, Announces Price Target of $8
Oppenheimer Remains a Buy on MannKind (MNKD)
MannKind Buy Rating Affirmed by Analyst Thomas Smith on Strong Revenue Growth and Promising Clinical Developments
MannKind Analyst Ratings
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (LENZ), MannKind (MNKD) and Aquestive Therapeutics (AQST)
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)